Bolt Biotherapeutics, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; filed March 29, 2023. This is an annual filing, not a standalone fourth-quarter report. Bolt is a clinical-stage biopharmaceutical company with no approved products or product-sales revenue.
Business and pipeline
Bolt is developing cancer immunotherapies using its Boltbody immune-stimulating antibody conjugate (ISAC) platform and myeloid biology expertise. Its lead candidate, BDC-1001, targets HER2-positive solid tumors. BDC-3042, a Dectin-2 agonist antibody, was in IND-enabling work. The company also has discovery and development collaborations with Toray, Genmab and Innovent, and clinical supply collaborations with Bristol Myers Squibb and Roche.
Key financial results
| Metric | FY2022 | FY2021 |
|---|---|---|
| Collaboration revenue | $5.7 million | $1.3 million |
| Research and development expense | $73.1 million | $75.7 million |
| General and administrative expense | $22.9 million | $18.4 million |
| Operating loss | $90.3 million | $92.8 million |
| Interest income | $2.2 million | $0.3 million |
| Net loss | $88.1 million | $98.6 million |
| Net loss per share, basic and diluted | $2.36 | $2.97 |
| Cash used in operating activities | $76.5 million | $57.1 million |
Revenue came from collaboration arrangements, not product sales. No meaningful product gross margin is reported. The company reported no income tax benefit, with a full valuation allowance against net deferred tax assets.
Liquidity, balance sheet and cash flow
- Cash, cash equivalents and marketable securities totaled $192.8 million at year-end 2022, down from approximately $271.6 million at year-end 2021.
- Total assets were $227.8 million; current assets were $172.7 million and current liabilities were $23.1 million.
- Total liabilities were $56.3 million, including $22.6 million of operating lease liabilities. The filing reports no outstanding debt.
- Net cash used in operations was $76.5 million. Investing activities provided $57.9 million, mainly from marketable-security maturities; financing activities provided $0.5 million.
- Management stated that available cash, cash equivalents and marketable securities were expected to fund operations for at least 12 months following the filing’s issuance date. This estimate depends on assumptions and development spending and may prove inaccurate.
Changes, outlook and risks
- Collaboration revenue increased by $4.5 million, primarily from progress on Genmab and Innovent work. R&D expense declined $2.5 million, mainly due to lower manufacturing costs, partly offset by higher clinical and facility expenses. G&A expense rose $4.5 million, mainly from personnel and facility costs.
- Net loss improved by $10.5 million, reflecting higher collaboration and interest income, lower R&D expense, and the absence of the $6.1 million 2021 preferred-stock-right fair-value expense. Operating cash use nevertheless increased by $19.4 million.
- BDC-1001 completed dose escalation; management reported preliminary tolerability through 20 mg/kg weekly and signs of antitumor activity, including partial responses and stable disease. These were early clinical findings, not confirmatory efficacy results. Phase 2 studies were expected to begin in 2023, including monotherapy and combination studies with nivolumab or pertuzumab.
- Management expected BDC-3042 to enter clinical development in 2023 and expected to select a next-generation ISAC clinical candidate by year-end 2023. These are forward-looking targets, not reported outcomes.
- BDC-2034 development was discontinued in August 2022 due to off-target toxicity associated with its targeting antibody. The company also paused other early research programs and prioritized selected ISAC and collaboration programs.
- Key risks include continued losses and future financing needs; dependence on BDC-1001 and unproven technology; clinical, regulatory and enrollment uncertainty; reliance on third-party manufacturing and suppliers; competition; intellectual-property and licensing risks; and macroeconomic, COVID-19 and supply-chain disruptions. Potential future equity financing could dilute shareholders.
- The company reported that a previously identified material weakness in internal control over financial reporting was remediated as of December 31, 2022; management judged controls effective. The auditor did not attest to internal-control effectiveness.
- No material legal proceedings were reported. The company had no product revenue, and profitability remains uncertain.
Important facts for investors to verify
- Whether the stated cash runway remains adequate as clinical-trial and manufacturing costs evolve, and the timing or terms of any additional financing.
- Updated BDC-1001 Phase 2 enrollment, safety, response durability and efficacy data, including results by tumor type and treatment combination.
- Whether BDC-3042 entered clinical development and whether the planned next-generation ISAC candidate was selected on schedule.
- Changes in collaboration scope, funding, deferred revenue and potential milestone or royalty prospects; disclosed milestone amounts are contingent, not assured revenue.
- Manufacturing and supply continuity, lease commitments, and the practical impact of the discontinued BDC-2034 program and research prioritization.